Evaxion Biotech A/S
NASDAQ:EVAX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Evaxion Biotech A/S
Total Equity
Evaxion Biotech A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Total Equity
$17m
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
28%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr14.8B
|
CAGR 3-Years
163%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Equity
$15.8m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€162.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr12.9B
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
|
Evaxion Biotech A/S
Glance View
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
See Also
What is Evaxion Biotech A/S's Total Equity?
Total Equity
17m
USD
Based on the financial report for Dec 31, 2025, Evaxion Biotech A/S's Total Equity amounts to 17m USD.
What is Evaxion Biotech A/S's Total Equity growth rate?
Total Equity CAGR 5Y
19%
The average annual Total Equity growth rates for Evaxion Biotech A/S have been 27% over the past three years , 19% over the past five years .
